TCR2 Therapeutics Inc., a Cambridge, MA-based immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, completed a $125m Series B financing.
The round was co-led by 6 Dimensions Capital and Curative Ventures with participation from new investors including Redmile Group, ArrowMark Partners, Hillhouse Capital Group, MiraeAsset Financial Group, Syno Capital, Haitong International Securities, Lucion Group, Sirona Capital, Alexandria Venture Investments and entities affiliated with Leerink Partners, and existing investors MPM Capital (MPM BioVentures 2014 and UBS Oncology Impact Fund by MPM Capital), F2 Ventures and Cathay Fortune Capital Investment.
The company will use the proceeds to advance two TRuC™-T cell programs through human proof-of-concept, including its lead solid tumor program TC-210 targeting mesothelin and support further expansion of its multi-format TRuC™ platform with a pipeline that includes dual-target TRuC™, immune cell enhancements and allogeneic technologies.
Led by Dr. Garry Menzel, Chief Executive Officer, TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors and blood cancers that utilize the full signaling power of complete T cell receptors (TCR) without the need for HLA-matching. TCR2’s proprietary multi-format TRuC™ platform reprograms the natural TCR complex to elicit rapid killing of cancer cells with long persistence and low cytokine release.
In conjunction with the funding, Dr. Wei Li, a Founding Partner of 6 Dimensions Capital and previously an Executive Partner at Fidelity Biosciences, along with Dr. Neil Gibson, whose extensive oncology research and development experience includes senior roles as the Chief Scientific Officer of OSI Pharmaceuticals, Pfizer Oncology, Regulus Therapeutics and COI Pharmaceuticals, joined TCR2’s board of directors.